Our commitment to research forms the very basis of the company's identity and Iberhospitex has been investing considerable effort in this area over a long period of time. R+D+I has become consolidated in the last five years to the extent that it is now a fundamental part of the company policy and strategy.
Iberhospitex possesses an R+D+i department dedicated to the research and development of new products for interventional cardiology, hospital care and biopolymers for medical applications.
Over the last five years, Iberhospitex has consistently set aside over 8% of its sales figure for R+D+I. Moreover, Iberhospitex actively participates in projects with other companies in the field of biotechnology. These projects are likely to crystallize in the short and medium term, bringing clear advantages over present therapeutic alternatives.
This continued research task will allow us to provide new products aimed at improving quality of life.